Physician profile
Michael Hakimi
NPI 1518109750
$6,255.91
in general payments reported to CMS, 2019-2025
20 companies · $3,449 in 2025
The $3,449 reported for 2025 was more than what 90% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $252 · 2021: $652 · 2022: $344 · 2023: $234 · 2024: $803 · 2025: $3,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,823 · Food and Beverage: $1,764 · Travel and Lodging: $812 · Gift: $87.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,823.41 |
| Food and Beverage | $1,764.13 |
| Travel and Lodging | $811.64 |
| Gift | $87.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Motiva USA, LLC | $3,179.24 | 2025 | |
| Allergan, INC. | $821.85 | 2019-2022 | |
| Abbvie INC. | $579.00 | 2023-2025 | |
| Revance Therapeutics, INC. | $434.40 | 2024-2025 | Daxxify |
| Solta Medical, A Division of Bausch Health US, LLC | $181.88 | 2021-2022 | |
| Lemaitre Vascular, INC. | $125.00 | 2024 | Hydro Lemaitre Valvulotome |
| Regeneron Healthcare Solutions, INC. | $122.10 | 2019 | |
| Apyx Medical Corporation | $116.91 | 2020 | |
| Zimmer Biomet Holdings, INC. | $111.66 | 2019 | |
| Integra Lifesciences Corporation | $103.15 | 2019 | |
| Alkermes, INC. | $102.15 | 2024 | Lybalvi |
| Sientra, INC. | $96.92 | 2021 | |
| Galderma Laboratories, L.P. | $95.34 | 2021-2024 | |
| Axogen | $53.10 | 2019 | |
| Scpharmaceuticals INC. | $26.94 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $25.53 | 2022 | |
| Bard Peripheral Vascular, INC. | $24.64 | 2021 | |
| Cvrx, INC. | $23.23 | 2024 | Barostim Neo System |
| Acelrx Pharmaceuticals, INC. | $17.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hakimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.